News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics to Present at March Medical Meetings
STAMFORD, Conn. , March 13, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
- Conference call today at 4:30 p.m. ET -
View HTML
Toggle Summary Cara Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results on March 9, 2017
STAMFORD, Conn. , March 02, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Completes Planned Enrollment of Eight-Week Multi-Dose Phase of Adaptive Trial of I.V. CR845 in Chronic Kidney Disease-Associated Pruritus
- Part A of the trial will evaluate three doses of I.V. CR845 versus placebo in 160 dialysis patients   - - Top-line data expected in first quarter of 2017  - STAMFORD, Conn. , Nov. 29, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and
View HTML
Toggle Summary Cara Therapeutics to Webcast Presentation at the 28th Annual Piper Jaffray Healthcare Conference
STAMFORD, Conn. , Nov. 22, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that
View HTML
Toggle Summary Cara Therapeutics to Webcast Presentation at the Stifel 2016 Healthcare Conference
STAMFORD, Conn. , Nov. 08, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that
View HTML
Toggle Summary Cara Therapeutics Reports Third Quarter 2016 Financial Results
-  Currently enrolling three late stage studies with CR845 totaling over 900 patients  -   -  Top line data expected in 1H 2017  - -  Conference call today at 4:30 p.m. ET  - STAMFORD, CONN ., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused
View HTML
Toggle Summary Cara Therapeutics to Present Data at Kidney Week 2016
STAMFORD, Conn. , Oct. 31, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced the
View HTML
Toggle Summary Cara Therapeutics to Announce Third Quarter 2016 Financial Results on November 3, 2016
STAMFORD, Conn. , Oct. 27, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that
View HTML
Toggle Summary Cara Therapeutics to Participate in October Medical Meetings
STAMFORD, Conn. , Oct. 12, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced its
View HTML